Review: The Nose as a Route for Therapy. Part 2 Immunotherapy

• Published in: Frontiers in allergy 2021-07, Vol.2, p.668781
• Main Authors: Padayachee, Yorissa, Flicker, Sabine, Linton, Sophia, Cafferkey, John, Kon, Onn Min, Johnston, Sebastian L, Ellis, Anne K, Desrosiers, Martin, Turner, Paul, Valenta, Rudolf, Scadding, Glenis Kathleen
• Format: Article
• Language: English
• Subjects: allergen immunotherapy; Allergy; epithelial barrier; interferon; microbiome; rhinovirus; vaccination
• ISSN: 2673-6101; 2673-6101
• DOI: 10.3389/falgy.2021.668781

The nose provides a route of access to the body for inhalants and fluids. Unsurprisingly it has a strong immune defense system, with involvement of innate (e.g., epithelial barrier, muco- ciliary clearance, nasal secretions with interferons, lysozyme, nitric oxide) and acquired (e.g., secreted immunoglobulins, lymphocytes) arms. The lattice network of dendritic cells surrounding the nostrils allows rapid uptake and sampling of molecules able to negotiate the epithelial barrier. Despite this many respiratory infections, including SARS-CoV2, are initiated through nasal mucosal contact, and the nasal mucosa is a significant "reservoir" for microbes including . This review includes consideration of the augmentation of immune defense by the nasal application of interferons, then the reduction of unnecessary inflammation and infection by alteration of the nasal microbiome. The nasal mucosa and associated lymphoid tissue (nasopharynx-associated lymphoid tissue, NALT) provides an important site for vaccine delivery, with cold-adapted live influenza strains (LAIV), which replicate intranasally, resulting in an immune response without significant clinical symptoms, being the most successful thus far. Finally, the clever intranasal application of antibodies bispecific for allergens and Intercellular Adhesion Molecule 1 (ICAM-1) as a topical treatment for allergic and RV-induced rhinitis is explained.